Navigation Links
Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
Date:9/17/2008

BETHESDA, Md., Sept. 17 /PRNewswire-USNewswire/ -- Findings from a trial of the accuracy of CT colonography (CTC) compared to complete colonoscopy in detecting large pre-cancerous polyps and colorectal cancers, coordinated by the American College of Radiology Imaging Network (ACRIN), raise several important issues for the public about colorectal cancer screening using a CT scan of the abdomen: the potential need for follow-up with complete colonoscopy in many cases, the real risk of undetected and unreported smaller growths with pre-cancerous potential, the reality of radiation risks relating to CT scans, as well as questions regarding patient acceptability of this test.

"Today's findings underscore the reality that many patients who have polyps detected by CT colonography will still have to undergo complete colonoscopy," explained Dr. Amy Foxx-Orenstein, D.O., FACG, President of the American College of Gastroenterology. Researchers found that as many as 12 percent to 17 percent of study participants screened by CTC would have to be referred for complete colonoscopy depending on the size threshold for reporting lesions in the colon. Of more significant concern, is that the researchers only reported growths in the colon 5 mm or larger, leaving unreported and therefore undetected an untold number of potentially high risk pre-cancerous growths.

"The College sees significant strengths in the proven benefits of visualizing pre-cancerous growths and removing them in a single examination during colonoscopy," commented Dr. Foxx-Orenstein.

"There is a tremendous body of evidence that shows that clearing the colon of polyps, including small polyps, significantly reduces colorectal cancer mortality. Because of its excellent sensitivity in detecting polyps and its potential for removing them and breaking the sequence of polyp to cancer in a single diagnostic and therapeutic intervention, complete colonoscopy is one of the most powerful preventive tools in clinical medicine. Until a radiographic test can meet that standard, gastroenterologists will continue to champion the lifesaving potential of colonoscopy," Foxx-Orenstein added.

Evaluating the Potential of CT Colonography - What Patients Should Know

When evaluating new potential screening technologies, including CT colonography, the ACG has focused its evaluation on several pieces of evidence including: sensitivity for identification of polyps of various sizes, standards for polyp removal, correlating patient risks (in this case from radiation exposure), frequency of exams and the economic impact to the healthcare system of separate diagnostic and therapeutic exams.

If all patients with a lesion measuring 5 mm or more on CT colonography in this study were referred for complete colonoscopy, the colonoscopy-referral rate would be 17 percent. In earlier findings by Dr. Pickhardt and his colleagues in 2004, at least 30 percent of patients undergoing virtual colonoscopy required conventional colonoscopy to remove polyps 6 mm or larger.

Radiation Risk

The issue of radiation exposure risk are long-term and lifetime risks. The results of the impact of patients undergoing CT and other radiologic exams for a variety of reasons will not be known for some time. With a proposed screening schedule of five years or less for CTC, depending upon the findings, the cancer risks from the CTC test itself are not insignificant. Although it is a challenge to define precise risk estimates related to low doses of radiation exposure, the ionizing radiation exposure from a single abdominal or chest CT may be associated with elevated risk for DNA damage and cancer formation. X-rays used in medical diagnostic procedures is the largest man-made source of radiation exposure to the population contributing some 14 percent of the total annual exposure from all sources. The U.S. Food and Drug Administration considers x-ray as a carcinogen.

Patient Acceptability

Patient acceptance is another key factor in evaluating the promise of a new technology. ACG notes that the CTC technology requires the same bowel preparation as complete colonoscopy. There is also evidence that due to the insertion of a tube in the rectum and insufflation of the abdomen with air or gas, the patients, who are not sedated and awake, tend to feel discomfort.

"It is important for patients to understand that CT colonography does not at present represent a painless or risk-free procedure, nor does it eliminate the need for bowel cleansing which patients report as a barrier to screening," explained Dr. Foxx-Orenstein.

Moreover, the American Cancer Society recently issued a Multi-Society Task Force Guideline on Colorectal Cancer which stated a preference for tests which prevent colorectal cancer. According to the American College of Gastroenterology, colonoscopy remains the preferred strategy for colorectal cancer screening and prevention. Three studies have shown that colonoscopy prevents about 80 percent of colorectal cancers from developing by removing pre-cancerous polyps.

"The public should recognize that there is no evidence that any radiographic test, including CT colonography, prevents the development of colorectal cancer," said Dr. Foxx-Orenstein.


'/>"/>
SOURCE American College of Gastroenterology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
2. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
3. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
4. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
5. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
6. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
9. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
10. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
11. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):